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Abstract
Sustained b-adrenergic receptors (bAR) activation leads to cardiac hypertrophy and prevents left ventricular (LV) atrophy
during LV unloading. The immediate signaling pathways downstream from bAR stimulation, however, have not been well
investigated. The current study was to examine the early cardiac signaling mechanism(s) following bAR stimulation. In adult
C57BL/6 mice, acute bAR stimulation induced significant increases in PI3K activity and activation of Akt and ERK1/2 in the
heart, but not in lungs or livers. In contrast, the same treatment did not elicit these changes in b1/b2AR double knockout
mice. We further showed the specificity of b2AR in this crosstalk as treatment with formoterol, a b2AR-selective agonist, but
not dobutamine, a predominantly b1AR agonist, activated cardiac Akt and ERK1/2. Acute bAR stimulation also significantly
increased the phosphorylation of mTOR (the mammalian target of rapamycin), P70S6K, ribosomal protein S6, GSK-3a/b
(glycogen synthase kinase-3a/b), and FOXO1/3a (the forkhead box family of transcription factors 1 and 3a). Moreover, acute
bAR stimulation time-dependently decreased the mRNA levels of the muscle-specific E3 ligases atrogin-1 and muscle ring
finger protein-1 (MuRF1) in mouse heart. Our results indicate that acute bAR stimulation in vivo affects multiple cardiac
signaling cascades, including the PI3K signaling pathway, ERK1/2, atrogin-1 and MuRF1. These data 1) provide convincing
evidence for the crosstalk between bAR and PI3K signaling pathways; 2) confirm the b2AR specificity in this crosstalk in vivo;
and 3) identify novel signaling factors involved in cardiac hypertrophy and LV unloading. Understanding of the intricate
interplay between b2AR activation and these signaling cascades should provide critical clues to the pathogenesis of cardiac
hypertrophy and enable identification of targets for early clinical interaction of cardiac lesions.
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Introduction
b-adrenergic receptors (bAR) are members of the G protein-
coupled receptor family [1]. Cardiomyocytes express all three
bAR subtypes- b1AR, b2AR, and, in some species, b3AR [2,3,4].
Different subtypes of bAR have the capacity to activate multiple
intracellular signaling pathways through different G proteins and
second messengers, thereby mediating diverse heart functions
under various conditions [5,6,7]. There is accumulating evidence
that sustained bAR activation leads to cardiac hypertrophy, which
represents an independent risk factor for cardiovascular morbidity
and mortality [8]. Thus, bAR blockers have become an esta-
blished treatment of chronic heart failure. On the other hand,
several lines of evidence suggest that selective bAR stimulation
may be beneficial in the setting of heart failure [9,10]. More
recently, clinical and experimental studies have shown that bAR
activation may prevent left ventricular (LV) atrophy during LV
unloading [11,12]. Hence, understanding the signaling mecha-
nisms under which bAR exert diverse roles in different cardiac
conditions is likely to provide a better therapeutic approach
towards treatment of heart failure. Our knowledge about the
mechanisms by which bAR activation promotes myocardial
growth was mostly acquired from in vitro systems or based on
studies using animal models of chronic systemic bAR agonist
administration [8]. The immediate signaling pathway(s) following
acute bAR stimulation have not been well investigated.
PI3K signaling contributes to many important cellular process-
es, including regulation of cell cycle, growth, survival and
migration [13]. Several genetic models with alterations of PI3K
and other signaling molecules, including phosphatase and tensin
homologue deleted from chromosome 10 (PTEN) and Akt, have
demonstrated altered cardiac phenotypes [14,15,16,17]. More-
over, we have previously demonstrated that the activity of the
PI3K signaling pathway during cardiac development is highly
regulated with the highest levels found during the fetal-neonatal
transition period and the lowest levels in the adult [18].
bAR stimulation has been shown to affect insulin signaling via
PI3K/Akt in cardiomyocytes [19]. In cultured cardiomyocytes,
bAR stimulation increases PI3K activity [20,21]. Both the b1AR
and b2AR have been reported to transactivate PI3K in vitro
[22,23]. Moreover, bAR stimulation-induced increases in heart
weight, contractile abnormalities, and myocardial fibrosis, and
cardiac ‘‘fetal’’ genes were markedly attenuated in PI3Kc-
knockout mice [24]. Our laboratory has shown that bAR-induced
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the regulation of cell proliferation and cellular protection against
apoptosis in neonatal cardiomyocytes [25,26]. Recently, we
further provided in vitro evidence for such bAR-PI3K crosstalk
and identified some critical signaling molecules involved [7]. The
crosstalk between bAR and PI3K signaling pathway in vivo,
however, has not been well studied, especially in a cardiac context.
Moreover, the early signaling events following bAR stimulation
preceding the onset of cardiac hypertrophy has not been
demonstrated. A more detailed picture of these early signaling
events would enable identification of targets for early clinical
interaction for the bAR-related cardiac lesions.
To elucidate the cardiac signaling mechanisms responsible for
the crosstalk between bAR and PI3K signaling pathway after
acute bAR agonist administration, wild type adult male C57BL/6
and b1/b2AR double knockout (b1/b2 DKO) mice were
employed. We demonstrated that multiple signaling molecules
downstream of PI3K are affected following acute bAR stimulation,
including Akt, P70S6/mTOR/S6 axis, GSK3a/b and FOXOs.
More important, two novel players, atrigin-1 and MuRF1, were
shown to be part of the early signaling cascade.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee of the Lifespan (Assurance Number: A3922-01;
Protocol Number: 002809). All efforts were made to minimize
suffering.
Materials
Isoproterenol (ISO), a nonspecific bAR agonist, and dobuta-
mine, a predominantly b1AR agonist [27], were obtained
from Hospira Inc., Lake Forest, IL. Formoterol, a b2AR-selective
agonist (displays a 330-fold selectivity for b2AR over b1AR, pKd
values are 8.12 and 5.58 respectively), was obtained from Tocris
Bioscience, Ellisville, MO. LY294002, a potent inhibitor of PI3K
was purchased from Santa Cruz Biotechnology, inc. (sc-201426).
All other chemicals and reagents were obtained from Sigma unless
stated otherwise.
Experimental animals
Three months old male C57BL/6 wild-type mice (The Jackson
Laboratory, Bar Harbor, ME) and b1/b2 DKO mice (Strain Name:
STOCK Adrb1
tm1Bkk Adrb2
tm1Bkk/J, Stock number: 003810, The
Jackson Laboratory) were used. Animals were fed standard
laboratory chow ad libitum. Mice were injected intraperitoneally
(i.p.) with ISO (1.25 mg/kg), dobutamine (1.7 mg/kg, the same
molar equivalent with ISO), formoterol (2.1 mg/kg, the same molar
equivalent with ISO) or saline for 30 min (unless otherwise
specified) before euthanized as previously described [7]. In some
experiments, mice were pretreated with DMSO (5%), LY294002
(1.4 mg/kg, i.p.) or H-89 (20 mg/kg, i.p.), a PKA inhibitor, for
30 min before the ISO treatment described above. Whole hearts
were harvested and LV was identified, dissected, flash frozen in
liquid nitrogen, and stored at 280uC. Left ventricular tissue lysates
were prepared as described [7].
PI3K Assays
Left ventricular lysates were prepared as described, and protein
concentrations were determined with the bicinchoninic acid assay
[7,18]. PI3K activity was determined with in vitro immunoprecip-
itation lipid kinase assay as described previously [7,18]. Briefly, left
ventricular lysates (0.5 mg unless noted otherwise) were immuno-
precipitated (IP) with anti-phosphotyrosine (pY) antibody (Upstate,
Charlottesville, VA), and L-a-phosphoinositide (Avanti Polar
Lipids, Alabaster, AL) was used as the lipid substrate (2 mg/
reaction), and converted to phosphoinositide 3-phosphate (PIP).
After incubation with c-
32P ATP (PerkinElmer, Inc., Boston, MA),
the final extracted reaction mixtures were spotted onto silica gel-
coated TLC plates (Whatman, Florham Park, NJ) and run in TLC
buffer (65% n-propanol, 0.54M acetic acid). The results were
analyzed by phosphorimaging (Bio-Rad Laboratories).
Western Blotting
Protein expression was evaluated by Western blotting as
previously described [26]. Protein samples were loaded and run
in either 4–12% Bis-Tris precast gels or 3–8% Tris-Acetate precast
gels (Invitrogen, Carlsbad, CA), blotted onto a PVDF membrane
(Bio-Rad, Hercules, CA), and detected by the following antibodies:
phospho-Akt (Ser473) antibody (R&D systems, Minneapolis, MN),
phospho-Akt (Thr308), total Akt, phospho-ERK1/2 (Thr202/
Tyr204), total ERK1/2, phospho-mTOR (Ser2448), total mTOR,
phospho-P70S6K (Thr389, Thr421/Ser424), total P70S6K,
phospho-S6 (Ser235/236, Ser240/244), total S6, phospho-GSK-
3a (Ser21), total GSK-3a, phospho-GSK-3b (Ser9), total GSK-3b,
phospho-FOXO1(Thr24)/FOXO3a(Thr32), phospho-FOXO3a
(Ser318/321, Ser253), total FOXO1 antibodies (Cell Signaling,
Danvers, MA), total FOXO3a and Actin antibodies (Millipore,
Billerica, MA).
Real Time Quantitative-PCR
Total RNA was extracted from ventricular tissue using TRIzol
reagent (Invitrogen, Carlsbad, CA), and further purified using
RNeasy MinElute Cleanup Kit (Qiagen, Hilden, Germany). RNA
concentration and purity were determined by spectrophotometry
(Thermo Scientific, Wilmington, DE). The reverse transcription
was performed using the Superscript III (Invitrogen) and Oligo
(dT) primers from total RNA (1 mg). Quantitative determination of
muscle-specific E3 ligases atrogin-1 (atrogin-1) and muscle ring
finger protein-1 (MuRF1) mRNA levels was performed by real-
time quantitative-PCR using specific TaqMan probes and
GAPDH as the endogenous control. The following primer/probe
pairs were used: atrogin-1, forward, 59-ACC AAA ACT CAG
TAC TTC CAT CAA GA-39, reverse, 59-TGT TGA AAG CTT
CCC CCA AA-39, probe,59-FAM-CAA AGG AAG TAC GAA
GGA GCG CCA TG-TAMRA-39; MuRF1, forward, 59-ACA
CAA CCT CTG CCG GAA GT-39, reverse, 59-ACG GAA ACG
ACC TCC AGA CA-39, probe, 59-FAM-AGG CTG CGA ATC
CCT ACT GGA CCA A-TAMRA-39; GAPDH, forward, 59-
ATG TTC CAG TAT GAC TCC ACT CAC G-39, reverse, 59-
GAA GAC ACC AGT AGA CTC CAC GAC A-39, probe, 59-
FAM-AAG CCC ATC ACC ATC TTC CAG GAG CGA GA-
TAMRA-39 [28]. Real Time Quantitative PCR was performed on
a 7500 Fast RT-PCR System (Applied Biosystems) using the
TaqMan Gene Expression Master Mix (Applied Biosystems). The
mRNA level was determined with the comparative Ct method
(2
-DDCt). Each sample was analyzed in triplicate.
Statistical Analysis
All data were expressed as mean 6 S.E. based on data derived
from multiple independent experiments. The intensity of bands
from Western blots was scanned with densitometry and digitally
analyzed using the Image J software (NIH). The statistical
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was considered statistically significant.
Results
Acute bAR stimulation induces increases in PI3K activity
and phosphorylation of Akt and ERK1/2 in adult mouse
heart
C57BL/6 mice were treated with saline or ISO for 30 min. Left
ventricular tissue lysates were subject to PI3K assay and Western
blotting. Acute ISO treatment increased phosphotyrosine-associ-
ated PI3K activity, Akt phosphorylation (Thr308 and Ser473), and
ERK1/2 phosphorylation in adult mice (Fig. 1A,B,C). Pretreat-
ment with LY294002, a potent PI3K inhibitor, abolished bAR
stimulation-induced activation of PI3K and Akt, confirming the
direct involvement of PI3K (Fig. 1D,E). In a subset of experiments,
mice were treated with ISO for various time periods shorter
(15 min) or longer than 30 min (1, 2, 4, or 6 hr). At all time points,
ISO treatment significantly increased Akt phosphorylation (Fig. 2).
The biggest increase, however, was found within the first hour
following ISO treatment and tapered off with time. The 30-mim
ISO treatment time point was then used for the experiments
described below to examine the acute effect of bAR stimulation.
We next further established the role of bAR in the transactivation
of PI3K/Akt. The effects of ISO on PI3K/Akt were completely
abrogated when the same treatment was performed on age- and
gender-matched b1/b2 DKO mice (Fig. 3A/B). Acute bAR
stimulation induced increase in ERK1/2 phosphorylation was also
abrogated in b1/b2 DKO mice (Fig. 3C). To determine if the
crosstalk is cardiac-specific, Western blotting was also performed
Figure 1. Acute bAR stimulation in vivo increases cardiac PI3K
activity andphophorylation ofAkt andERK1/2. Adult male C57BL/
6 mice were treated with vehicle control or isoproterenol (ISO, 1.25 mg/
kg, i.p.) for 30 min. (A) Left ventricular tissue lysates were IP with an anti-
pY antibody and subjected to in vitro lipid kinase assay. PIP, the
phosphorylated end-product. The bar graph shows the densitometric
scanning results of the measurement of PI3K activities in the control
(n=6) and ISO-treated (n=6) mice. (B, C) Representative Western blot
analyses were performed on LV tissue lysates with antibodies against
phospho-Akt (Thr308), phospho-Akt (Ser473), total Akt, phospho-ERK1/2
(Thr202/Tyr204) andtotalERK1/2. Thebargraphs showthedensitometric
scanning results from two individual experiments (n=6). In another
series of experiments, mice were pretreated with vehicle (5% DMSO) or
LY294002 (LY, 1.4 mg/kg, i.p.) for 30 min before the ISO treatment. In
vitro lipid kinase assay (D) and Western blot analyses (E) were performed
as described above. The bar graph shows the densitometric scanning
results in the control (n=6), ISO (n=6), and LY/ISO (n=6) groups. In all
Western blotting experiments,data were normalized with individual total
protein levels. *, p,0.05 versus vehicle control.
doi:10.1371/journal.pone.0026581.g001
Figure 2. The time course of the effect of bAR stimulation in
vivo on phophorylation of Akt, ERK1/2, P70S6K, S6, GSK-3a/b
and FOXO3a. Adult male C57BL/6 mice were treated with vehicle
control or isoproterenol (ISO, 1.25 mg/kg, i.p.) for the indicated time.
Shown are representative Western blots performed on LV tissue lysates
with antibodies against phospho-Akt (Thr308), phospho-Akt (Ser473),
phospho-ERK1/2 (Thr202/Tyr204), phospho-P70S6K (Thr389), phospho-
P70S6K (Thr421/Ser424), phospho-S6 (Ser235/236), phospho-S6
(Ser240/244), phospho-GSK-3a (Ser21), phospho-GSK-3b (Ser9), and
phospho-FOXO3a (Ser318/321). Blots of individual total protein and
actin were also included.
doi:10.1371/journal.pone.0026581.g002
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treated mice. Acute bAR stimulation did not increase Akt
phosphorylation in the lung, kidney (Fig. 4A,B) or liver (data not
shown). Interestingly, acute bAR stimulation significantly in-
creased the phosphorylation of ERK1/2 in the kidney but not in
the lung (Fig. 4A,C). It is well established that bAR stimulation can
induce cellular effects via the activation of G proteins/cAMP/
PKA signaling pathway. It is not known, however, if the cAMP/
PKA cascade is required for the crosstalk between acute bAR
stimulation and PI3K in vivo. Our previous study based on in vitro
model suggests that cAMP/PKA pathway may not be needed for
such crosstalk [7]. To investigate this, mice were pretreated with
H-89, a PKA inhibitor, for 30 min before injection with ISO for
30 min. As expected, ISO treatment significantly increased
cardiac PI3K activity and phosphorylation of Akt and FOX-
O1(Thr24) which were not affected by pretreatment with H-89
(Fig. 5).This suggests that the cAMP/PKA signaling pathway is
not directly involved with bAR stimulation-mediated activation of
PI3K signaling pathway. Taken together, these data provide solid
evidence for a crosstalk between bAR and PI3K signaling pathway
in adult mouse heart.
Acute bAR stimulation- induced increase in
phosphorylation of Akt and ERK1/2 is b2AR-specific
As mentioned earlier, both b1AR and b2AR are expressed in
the heart. To assess which subtype of bAR is responsible for ISO-
induced increase in phosphorylation of Akt and ERK1/2, mice
were treated with saline, dobutamine (a predominantly b1AR
agonist) or formoterol (a b2AR-selective agonist) for 30 min.
Acute b2AR stimulation with formoterol induced significant
increases in PI3K activity (Fig. 6A) and phosphorylation of
both Akt (Thr308, Ser473) and ERK1/2 (Fig. 6). In contrast,
acute b1AR stimulation with dobutamine had no effect (Fig. 6B).
In a subset of experiments, we further examined changes in
phosphorylation in other downstream signaling factors. Consis-
tent with results shown in Fig. 6, acute treatment with formoterol,
but not dobutamine, increased phosphorylation of P70S6
(Thr389 and T421/S424), S6 (S235/236 and S240/244), GSK3a
(Ser21), GSK3b (Ser9) and FOXO3a (S318/321) (Fig. 7). These
results suggest that the effects of acute bAR stimulation on PI3K
signaling pathway and ERK1/2 in adult mouse heart are b2AR-
specific.
Acute bAR stimulation increases phosphorylation of
other signaling factors downstream of PI3K
We next examined other signaling molecules downstream of
PI3K following the same ISO treatment. The mammalian target
of rapamycin (mTOR) is an important downstream effector
of PI3K/Akt pathway [29]. Following acute ISO treatment,
phosphorylation of mTOR (Ser2448) was markedly increased
(Fig. 8A). Phosphorylation of P70S6K (ribosomal protein S6 kinase
1), immediately downstream of mTOR [30], was significantly
increased at both the Thr389 and Thr421/Ser424 sites (Fig. 8B).
Furthermore, phosphorylation of ribosomal protein S6 (Ser235/
236, S240/244), the effector of p70S6K, was also significantly
increased after acute bAR stimulation in mouse heart (Fig. 8C).
Glycogen synthase kinase-3 (GSK-3) is another critical down-
stream element of the PI3K/Akt signaling pathway. These kinases
are key signaling mediators in myocardial hypertrophy and
progressive heart failure [31]. As shown in Fig. 9, acute bAR
stimulation induced a significant increase in the phosphorylation
of both GSK-3a (Ser21) and GSK-3b (Ser9).
The forkhead box family of transcription factors (FOXOs) is
implicated in the regulation of a variety of cellular processes,
including the cell cycle, apoptosis, DNA repair, stress resistance,
and metabolism. FOXOs proteins are negatively regulated by the
PI3K/Akt signaling pathway [32]. We have demonstrated, for the
first time, that acute bAR stimulation induced significant increases
in the phosphorylation of both FOXO1 (Thr24) and FOXO3a
(Thr32, Ser318/321, Ser253) in vivo (Fig. 10). Taken together,
these data indicate that acute bAR stimulation-induced signaling
cascade involves multiple factors downstream of Akt, including
mTOR/P70S6K/S6, GSK-3a/b and FOXO1/3a.
Acute bAR stimulation reduces the mRNA levels of
atrgin-1 and MuRF1
It has been shown that atrogin-1 and MuRF1 are associated
with hypertrophy and atrophy processes in skeletal muscle through
the PI3K/Akt signaling pathway [33,34]. To investigate whether
cardiac atrogin-1 and MuRF1 are affected by acute bAR
stimulation, we examined their mRNA levels by real-time
quantitative PCR. As shown in Fig. 11A, bAR stimulation
induced a time-dependent reduction of both atrogin-1 and
MuRF1 mRNA levels. The trend in reduction in the mRNA
levels can be seen as early as one hour following ISO treatment.
Figure 3. Acute bAR stimulation doesn’t affect the activity of PI3K/Akt or ERK1/2 in b1/b2DKO mouse heart. Adult male b1/b2 double
knockout mice were treated with vehicle control or isoproterenol (ISO, 1.25 mg/kg, i.p.) for 30 min. (A) Left ventricular lysates were subjected to in
vitro lipid kinase assay as described above. The bar graph shows the densitometric scanning results of the measurement of cardiac PI3K activities in
the control (n=3) and ISO-treated (n=3) mice. (B, C) Representative Western blot analyses were performed on LV tissue lysates as described above.
The bar graphs show the densitometric scanning results from three seperate experiments. Data are normalized with individual total protein levels.
doi:10.1371/journal.pone.0026581.g003
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4 hours. A similar reduction (50%,60%) in the mRNA levels of
both atrogin-1 and MuRF1 was seen in the ISO-treated mice
(Fig. 11B/C). This is the first demonstration in mouse heart that
bAR stimulation reduces the mRNA levels of atrogin-1 and
MuRF1.
Discussion
In the present study, we set out to elucidate the early signaling
events that mediate the effect of acute bAR stimulation in mouse
heart. Our results provide convincing in vivo evidence for the
crosstalk between bAR and PI3K signaling pathway. We
demonstrate that the bAR transactivation of PI3K/Akt pathway
is b2AR-specific and confines to the heart. Many known signaling
factors downstream of PI3K, including the mTOR/P70S6K/S6
axis, GSK-3a/b, and FOXO1/FOXO3a, were shown to be
involved. Although these cascades have been well investigated, the
link between bAR and these signaling pathways has not been
systematically characterized in vivo, especially in the cardiac
context. More important, we demonstrate, for the first time, that
Figure 5. Acute bAR stimulation induced-transactivation of
PI3K signaling pathway is PKA-independent. Adult male C57BL/6
mice were pretreated with vehicle (5% DMSO) or H-89 (20 mg/kg, i.p.)
for 30 min before treatment with control (saline) or isoproterenol (ISO,
1.25 mg/kg, i.p.) for 30 min. (A) In vitro lipid kinase assay was
performed as described. PIP, the phosphorylated end-product. The
bar graph shows the densitometric scanning results of the measure-
ment of PI3K activities in the control, ISO-treated and H-89 + ISO-
treated mice (n=4). (B, C) Representative Western blot analyses were
performed on LV tissue lysates with antibodies against phospho-Akt
(Thr308), phospho-Akt (Ser473), phospho-FOXO1 (Thr24), total Akt and
total FOXO. The bar graphs show the densitometric scanning results.
Data are normalized with individual total protein levels and represent
means 6 S.E. of percent change in protein phosphorylation relative to
that of the control. *, p,0.05 versus the control.
doi:10.1371/journal.pone.0026581.g005
Figure 4. Acute bAR stimulation induced increase in phosphor-
ylation of Akt is cardiac-specific. Adult male C57BL/6 mice were
treated with vehicle control (saline) or isoproterenol (ISO, 1.25 mg/kg,
i.N) for 30 min. (A) Representative Western blot analyses were
performed on lung or kidney tissue lysates with antibodies against
phospho-Akt (Thr308), phospho-Akt (Ser473), total Akt, phospho-ERK1/
2 (Thr202/Tyr204) and total ERK1/2. (B, C) The bar graphs show the
densitometric scanning results from two seperate experiments (n=6).
Data are normalized with individual total protein levels and represent
means 6 S.E. of percent change in protein phosphorylation relative to
that of vehicle control. *, p,0.05 versus vehicle control.
doi:10.1371/journal.pone.0026581.g004
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mouse heart.
The levels and activity of the cardiac PI3K signaling pathway
are tightly controlled during development. The highest activity is
found in late gestation and early postnatal life and then decreases
dramatically in older animals [18]. We have in vitro and in vivo
evidence showing that bAR stimulation induces activation of
cardiac PI3Ka but not the other isoforms of PI3K [7]. However,
the responsible signaling mediators downstream of PI3K after
acute bAR stimulation have not been well established. The results
of the current study are the first systematical identification of
multiple important signaling factors for such bAR-PI3K crosstalk.
Akt is a serine/threonine protein kinase downstream of PI3K.
Full activation of Akt requires phosphorylation at both Thr308 [by
3–phosphoinositide–dependent protein kinase 1 (PDPK1)] and
Ser473 (by a putative PDPK2) [35,36]. In mouse heart, acute bAR
stimulation increases the phosphorylation of Akt at both the
Thr308 and Ser473 sites (Fig. 1B). ERK1/2 is another important
signaling effector involved in development of bAR-mediated
cardiac hypertrophy [37,38]. Following acute bAR stimulation,
ERK1/2 is also activated (Fig. 1C). It is likely, that the signaling
cascades responsible for bAR-induced cardiac hypertrophy are not
confined to PI3K and ERK1/2. Moreover, it is possible that there
are different mechanisms underlying induction of hypertrophy,
depending on the pathological stimuli [39].
b1/b2 DKO mice are viable, fertile, normal in size and do not
display any gross physical or behavioral abnormalities [40]. It has
been shown that the impact of b1/b2AR loss on basal physiological
functions such as heart rate, blood pressure, or metabolic rate is
remarkably modest. Hence, b1/b2 DKO mice represent a useful
model for the study of bAR-modulated cardiac functions in vivo
[40]. We showed that transactivation of PI3K and the subsequent
activation of Akt and ERK1/2 following acute bAR stimulation
Figure 6. Acute bAR stimulation induced increase in phosphor-
ylation of Akt and ERK1/2 is b2AR-specific. C57BL/6 mice were
treated with vehicle control, dobutamine (Dob., 1.7 mg/kg, i.p.), or
formoterol (For., 2.1 mg/kg, i.p.), for 30 min. (A) In vitro lipid kinase
assay was performed as described except with higher amount of LV
lysates (1 mg). PIP, the phosphorylated end-product. The bar graph
shows the densitometric scanning results of the measurement of PI3K
activities in the control, Dob.-treated and For.-treated mice (n=4). (B)
Representative Western blot analyses were performed on left ventric-
ular lysates with antibodies against phospho-Akt (Thr308), phospho-Akt
(Ser473), total Akt, phospho-ERK1/2 (Thr202/Tyr204) and total ERK1/2.
The bar graphs show the densitometric scanning results from two
seperate experiments (n=5). Data are normalized with individual total
protein levels and represent means 6 S.E. of percent change in protein
phosphorylation relative to that of vehicle control. *, p,0.05 versus
vehicle control.
doi:10.1371/journal.pone.0026581.g006
Figure 7. Acute b2AR stimulation induced increases in phos-
phorylation of P70S6, S6, GSK3a, GSK3b and FOXO3a. C57BL/6
mice were treated with vehicle control, dobutamine (Dob., 1.7 mg/kg,
i.p.), or formoterol (For., 2.1 mg/kg, i.p.), for 30 min. Shown are
representative Western blots performed on left ventricular lysates with
antibodies against phospho-P70S6K (Thr389), phospho-P70S6K
(Thr421/Ser424), phospho-S6 (Ser235/236), phospho-S6 (Ser240/244),
phospho-GSK-3a (Ser21), phospho-GSK-3b (Ser9), phospho-FOXO3a
(Ser318/321). Blots of individual total protein and activ were also
included.
doi:10.1371/journal.pone.0026581.g007
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evidence for the cardiac bAR-PI3K crosstalk in vivo.
There is increasing evidence to support a differential role of
b1AR and b2AR in terms of regulation of cardiac function and
alterations in cardiac structure [6,26,41,42,43]. For example,
b1AR has been shown to mediate pro-apoptotic responses while
b2AR mediates anti-apoptotic responses in cardiomyocytes
[26,43]. b2AR signaling has a lower overall effect on contractility
than b1AR signaling does [44]. Coupled to Gai, b2AR signaling
has been demonstrated to induce the recruitment and activation of
other signaling molecules, including PI3K/Akt and ERK
[5,22,44,45]. We have previously shown bAR stimulation-induced
activation of PI3K signaling pathway is b2AR-specific in H9c2
cardiomyoblasts, a b2AR predominant cell line [7]. In compar-
ison, b1AR comprises approximately 70–80% of the total bAR
population in healthy heart [42]. Despite these differences of bAR
subtype abundance in H9c2 cells and in mouse heart, acute bAR
stimulation-induced activation of PI3K signaling pathway appears
to be b2AR-specific. It is unknown, however, whether or not
chronic bAR stimulation-induced cardiac hypertrophy is solely
mediated by b2AR. It has been reported in cultured rat neonatal
cardiomyocytes that bAR-induced hypertrophy is mediated
primarily by the b1AR subtype [46]. This discrepancy may reflect
the fundamental differences between in vitro and in vivo systems.
The in vivo data shown here are novel and add new insights to our
understanding regarding the characteristics among bAR subtypes.
This crosstalk may be tissue-specific since the same bAR
stimulation did not activate Akt in the lungs, kidneys (Fig. 4) or
liver. Acute bAR stimulation, however, did activate ERK1/2 in
Figure 8. Acute bAR stimulation in vivo induces increases in the phophorylation of mTOR, P70S6K and S6. C57BL/6 mice were treated
with vehicle control or isoproterenol (ISO, 1.25 mg/kg, i.p.) for 30 min. Representative Western blot analyses were performed on left ventricular
lysates with antibodies against (A) phospho-mTOR (Ser2448) and total mTOR; (B) phospho-P70S6K (Thr389, Thr421/Ser424) and total P70S6K; (C)
phospho-S6 (Ser235/236, Ser240/244) and total S6. The bar graphs show the densitometric scanning results from two seperate experiments (n=6).
Data are normalized with individual total protein levels. *, p,0.05 versus vehicle control.
doi:10.1371/journal.pone.0026581.g008
Figure 9. Acute bAR stimulation in vivo induces increases in the
phophorylation of GSK-3a and GSK-3b. C57BL/6 mice were treated
with vehicle control or isoproterenol (ISO, 1.25 mg/kg, i.p.) for 30 min.
Representative Western blot analyses were performed on left ventric-
ular lysates with antibodies against phospho-GSK-3a (Ser21), total GSK-
3a, phospho-GSK-3b (Ser9), and total GSK-3b. The bar graphs show the
densitometric scanning results from two seperate experiments (n=6).
Data are normalized with individual total protein levels. *, p,0.05
versus vehicle control.
doi:10.1371/journal.pone.0026581.g009
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interesting and warrant further future investigation.
Activation of Akt and mTOR plays a crucial part in the
regulation of cell growth and proliferation by monitoring nutrient
availability, cellular energy levels, oxygen levels and mitogenic
signals [29,47,48]. One of the most extensively characterized
downstream targets of mTOR is P70S6K, which is pivotal to the
regulation of protein synthesis, via the phosphorylation and
activation of its major effector, ribosomal protein S6 [29,30]. In
the present study, we demonstrated that acute bAR stimulation in
adult mouse heart increased the phosphorylation of the whole
mTOR/P70S6K/S6 signaling axis at multiple sites. Considering
the important roles of growth promotion by the mTOR/P70S6K/
S6 signaling axis, it is plausible to reason that chronic bAR
activation may lead to cardiac hypertrophy via this signaling
pathway.
Akt-mediated phosphorylation of GSK-3 is inhibitory [49]. It is
believed that GSK-3 inhibition induced-cardiac hypertrophy is
independent of the mTOR pathway [31,50]. It has been shown
that GSK-3b inactivation occurs in response to bAR agonists [20].
More recent studies also indicate that expression of inactivation-
resistant GSK-3a/b isoforms avert the pathological hypertrophy
caused by chronic ISO stress [51]. In isolated C57BL/6 mice
hearts, acute ISO exposure resulted in significant GSK-3b, but not
GSK-3a, phosphorylation. In most previous studies, particular
attention has focused on GSK-3b because it is regarded as the
predominant isoform, but increasingly GSK-3a has been consid-
ered to play equally important roles. For example, it has been
shown that up-regulation of GSK-3a inhibited cardiac growth and
pressure overload-induced cardiac hypertrophy which is mediated
through inhibition of ERK [52]. Our data provide strong evidence
that acute bAR stimulation induces phosphorylation (inhibition) of
both GSK-3a and GSK-3b in vivo.
Phosphorylation of FOXOs by Akt is inhibitory and leads to
nuclear exclusion and the inhibition of the forkhead transcrip-
tional program [53]. Three members of the FOXOs, FOXO1,
FOXO3a, and FOXO4, have been implicated in regulating
diverse cellular functions including differentiation, metabolism,
proliferation, and survival [32,54]. In cardiomyocytes, it has been
established that FOXO1 and FOXO3a regulates apoptotic
responses [55] and cell size [56], respectively. Recently, FOXOs
have also been shown to promote atrophy in skeletal muscle
[34,57]. It is, however, not known if the regulation and function of
FOXOs in the heart are under the control of bAR. Our study
provides evidence, for the first time, that acute bAR stimulation
Figure 10. Acute bAR stimulation in vivo induces an increase in
the phophorylation of FOXO1 and FOXO3a. C57BL/6 mice were
treated with vehicle control or isoproterenol (ISO, 1.25 mg/kg, i.p.) for
30 min. Representative Western blot analyses were performed on left
ventricular lysates with antibodies against phospho-FOXO1(Thr24)/
FOXO3a(Thr32), phospho-FOXO3a (Ser318/321, Ser253), total FOXO1
and total FOXO3a. The bar graphs show the densitometric scanning
results from two seperate experiments (n=6). Data are normalized with
individual total protein levels. *, p,0.05 versus vehicle control.
doi:10.1371/journal.pone.0026581.g010
Figure 11. Acute bAR stimulation time-dependently decreases
the levels of atrogin-1 and MuRF1 mRNA in mouse heart. Adult
male C57BL/6 mice were treated with vehicle control or isoproterenol
(ISO, 1.25 mg/kg, I.p.) for up to six hours (A). In a separate experiment,
mice were treated with vehicle control or ISO for four hours. The mRNA
levels of atrogin-1 (B, n=3) and MuRF1 (C, n=3) were determined by
real time quantitative PCR using specific TaqMan probes and
normalized to GAPDH. The plot lines or bar graphs represent the
means 6 S.E of percent change in mRNA level relative to that of vehicle
control. *, p,0.05 versus vehicle control.
doi:10.1371/journal.pone.0026581.g011
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mouse heart.
It has been extensively investigated that atrogin-1 and MuRF1
are common mediators in several models of skeletal muscle
hypertrophy and atrophy. The levels of atrogin-1 and MuRF1 are
regulated by the growth factor/Akt signaling axis through direct
transcriptional regulation by FOXOs [33,34,57]. b2AR–agonists
has also been shown to increase skeletal muscle strength in normal
volunteers [58] and in a small number of patients [59]. In a
cardiac context, atrogin-1 and MuRF1 have been demonstrated to
inhibit cardiac hypertrophy [56,60,61]. It was also shown that
atrogin-1 and MuRF1 regulate cardiac myosin-binding protein C
which is related to familial hypertrophic cardiomyopathy [28].
Moreover, recent clinical and experimental studies have suggested
that bAR activation may prevent LV atrophy during LV
unloading [11,12], with the mechanism unknown. However, it
has not been reported whether or not atrogin-1 and MuRF1 are
involved in the bAR stimulation-induced cardiac hypertrophy
and/or the anti-atrophic effect. Our finding is the first to
demonstrate the link from bAR to atrogin-1 and MuRF1 in the
heart, presumably via PI3K/Akt/FOXOs. Further study of this
crosstalk should yield useful insights that may have important
clinical implications.
In summary, our data suggest that crosstalk between bAR and
PI3K signaling pathway activates multiple downstream signaling
effectors and cascades in vivo. Our data support a model depicted
in Fig. 12, where acute stimulation of the b2AR activates PI3K,
which affects the activities of ERK1/2, Akt and its downstream
signaling cascades, including mTOR/P70S6K/S6 axis, GSK-3a/
b, FOXOs, atrogin-1 and MuRF1. These data provide mecha-
nistic and signaling insights for the pathophysiological conse-
quences induced by chronic bAR stimulation.
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